Here are the DEF 14A proxy statements from Apyx Medical Corporation (APYX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow APYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APYX filings page.
Apyx Medical Corporation is soliciting proxies for its 2026 Annual Meeting of Stockholders on August 6, 2026, where holders will vote to elect five directors, ratify RSM US LLP as auditor, approve a non-binding say-on-pay resolution, and approve the 2026 Share Incentive Plan.
Stockholders of record at the close of business on June 15, 2026, when 41,912,040 common shares were outstanding, are entitled to vote. The proxy statement also reviews 2025 developments, including FDA 510(k) clearance and commercial launch of the AYON body contouring system, Renuvion’s launch in China, and a November 2025 equity offering of 2,762,431 shares at $3.62 for approximately $9.1 million in net proceeds.
The filing details executive and director compensation, with CEO Charles D. Goodwin’s 2025 total compensation of $1,233,863, an at-risk bonus framework tied to performance, significant stock option grants, and an executive compensation clawback policy. It also highlights governance structures such as a majority-independent board, four standing committees, a lead independent director, a code of ethics, and an insider trading policy.